← 返回

肿瘤内 CD8+ T 细胞中激活转录因子-4 的诱导维持其活力和抗肿瘤活性

英文原题:Induction of the activating transcription factor-4 in the intratumoral CD8+ T cells sustains their viability and anti-tumor activities.

查看英文原题

Induction of the activating transcription factor-4 in the intratumoral CD8+ T cells sustains their viability and anti-tumor activities.

PubMed 2022/09/05(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤微环境(TME)的免疫抑制因子削弱了瘤内细胞毒性CD8+ T淋巴细胞(CTL)的活力并耗竭其活性,从而逃避免疫监视并降低免疫治疗的获益。为了对抗这种抑制并提高治疗方案的疗效,识别和理解CD8+ T细胞中响应TME应激和肿瘤衍生因子的关键调控因子至关重要。

在此,我们利用一种新型的Atf4 ΔCD8小鼠模型(该模型在CD8+细胞中特异性缺失ATF4),研究了活化转录因子-4(ATF4)在CTL中的调控作用及其重要性。CD8+ T细胞中ATF4的诱导发生在抗原刺激响应中,并且在暴露于肿瘤衍生因子和TME条件后进一步增加。在这些条件下,ATF4在维持CD8+ T细胞的存活和活性方面发挥了关键作用。相反,在小鼠CD8+ T细胞中选择性消融ATF4使得这些Atf4 ΔCD8宿主易于出现植入肿瘤的加速生长。与野生型对应细胞相比,瘤内ATF4缺陷的CD8+ T细胞比例不足,并表现出活化受损和凋亡增加。这些发现确定ATF4是TME中CD8+ T细胞活力和活性的重要调控因子,并提示在抗癌治疗中应谨慎使用可能破坏ATF4这些功能的药物。

展开英文摘要原文

Immune suppressive factors of the tumor microenvironment (TME) undermine viability and exhaust the activities of the intratumoral cytotoxic CD8 + T lymphocytes (CTL) thereby evading anti-tumor immunity and decreasing the benefits of immune therapies. To counteract this suppression and improve the efficacy of therapeutic regimens, it is important to identify and understand the critical regulators within CD8 + T cells that respond to TME stress and tumor-derived factors.

Here we investigated the regulation and importance of activating transcription factor-4 (ATF4) in CTL using a novel Atf4 ΔCD8 mouse model lacking ATF4 specifically in CD8 + cells. Induction of ATF4 in CD8 + T cells occurred in response to antigenic stimulation and was further increased by exposure to tumor-derived factors and TME conditions.

Under these conditions, ATF4 played a critical role in the maintenance of survival and activities of CD8 + T cells. Conversely, selective ablation of ATF4 in CD8 + T cells in mice rendered these Atf4 ΔCD8 hosts prone to accelerated growth of implanted tumors. Intratumoral ATF4-deficient CD8 + T cells were under-represented compared to wild-type counterparts and exhibited impaired activation and increased apoptosis.

These findings identify ATF4 as an important regulator of viability and activity of CD8 + T cells in the TME and argue for caution in using agents that could undermine these functions of ATF4 for anti-cancer therapies.

论文信息

作者
Lu Z、Bae EA、Verginadis II、Zhang H、Cho C、McBrearty N、George SS、Diehl JA
第一作者单位
Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, 380 S. University Ave, Hill 316, Philadelphia, PA, 19104, USA.United States
通讯作者单位
Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, 380 S. University Ave, Hill 316, Philadelphia, PA, 19104, USA. syfuchs@vet.upenn.edu.United States
期刊
Cancer immunology, immunotherapy : CII2023 Apr
原文标识
PubMed 36063172 · DOI 10.1007/s00262-022-03286-2